Third, KRAS mutations are driver “hotspot” mutations that play a critical role in tumorigenesis and are likely to be clonally expressed in all tumor cells present in a patient with cancer (4, 10), and thus targeting KRAS mutations may overcome tumor antigen heterogeneity (8). The gene discussed is KRAS; the disease is cancer.